Molecular Biomarker Analysis
InquiryOverview of Molecular Biomarker
Through sophisticated molecular biology techniques and advanced bioinformatics tools, Protheragen is committed to unraveling the molecular mechanisms of obesity development and identifying and validating a series of biomarkers with potential clinical value. These biomarkers can not only serve as early indicators for obesity risk assessment but also provide precise targets for the development of Anti-obesity Therapy Pharmacodynamic Studies, accelerating the process of research and development of treatment options for obesity and its complications. Biomarkers are playing an increasingly important role in improving the translatability of preclinical research. Our researchers utilize in vivo and in vitro experiments to fully validate biomarkers in preclinical settings to ensure their sensitivity, specificity, and reproducibility.
One-stop In-depth Preclinical Molecular Biomarker Profiling
Our preclinical research closely focuses on the pathophysiological process of obesity, from adipocyte differentiation, energy metabolism regulation, inflammatory response gut microbiota, and other dimensions, to provide a solid scientific foundation for the development of anti-obesity therapies. We provide many different types of biomarker testing services.
Molecular Biomarker Profiling
Whether you want to analyze small molecule biomarkers or large molecule biomarkers, we provide the most satisfactory analytical solutions. Depending on the client's needs and molecular target specificity, our researchers plan the entire analytical program for the client.
- Cell modeling: Our researchers provide a range of services such as cell culture, model construction, staining, validation, and analysis.
- Animal modeling: Our researchers provide a wide range of services including professional animal feeding, model construction, differentiation induction, validation, animal execution, and metrics analysis.
- Profiling: Our company provides professional biomarker analysis including but not limited to ligand binding assay, liquid chromatography-high-resolution mass spectrometry (LC-HRMS) analysis, LC-MS analysis, chromatography, western blotting, and enzyme-linked immunosorbent assays (ELISA).
Anti-Obesity Therapy-Related Biomarker
Our company utilizes biomarkers to monitor the response of animal models to anti-obesity therapies in real-time. Moreover, we offer pre- and post-treatment biomarker comparison services. Our company offers not only common biomarker testing services but also novel biomarker discovery and screening services.
Data Analysis
Our professional bioinformatics team provides clients with data organization, classification, screening, and visualization services for the large amount of data analyzed for biomarkers. We provide clients with high-quality and complete data reports.
Workflow
Our company provides a one-stop shop for the analysis of molecular biomarkers for preclinical anti-obesity therapies. We are committed to accelerating our clients' programs through pharmacological studies.
Applications
- Molecular biomarker analysis can be used to specifically label normal biological processes, pathogenic processes, or pharmacological responses, among others.
- Molecular biomarker analysis can be used to assess physiologic, biochemical, immunologic, cellular, and genetic alterations.
- Pharmacokinetic biomarkers combined with pharmacokinetics confirm target-disease relationships and guide dose selection.
Advantages of Us
- Our highly trained and talented team has extensive experience in the discovery, screening, and analysis of molecular biomarkers.
- Not only do we focus on host biomarkers, but gut flora biomarkers are also the focus of our analysis.
- Relying on our high-throughput analytical services and data processing team, we deliver every project on time to shorten the project cycle time.
With an elite team of senior experts and equipped with leading international research facilities, we are committed to providing comprehensive and high-quality customized obesity research solutions.
Our researchers design and implement targeted research programs, analyze the factors associated with obesity, validate the effectiveness of interventions, and develop personalized obesity management programs. This includes precise analysis of obesity mechanisms, detection of obesity-related biomarkers, metabolomics studies, and the development of big data-based obesity risk assessment models to meet the growing demand for in-depth obesity research in the preclinical, public health, and life sciences sectors.
Publication Data
Technology: Oil red O staining, Western blotting, High-performance liquid chromatography photo-diode array (HPLC-PDA), Cell viability assay
Journal: Nutrients
Published: 2018
IF: 4.8
Results: In this study, researchers evaluated the anti-obesity therapy of Spirulina maxima 70% ethanol extract (SM70EE) with the help of in vivo and in vitro obesity models. The researchers used western blot to analyze the expression levels of down-regulated adipogenic proteins (e.g. CCAAT/enhancer-binding protein alpha (C/EBPα), peroxisome proliferator-activated receptor γ (PPARγ), adipocyte protein 2 (aP2)) and lipogenic proteins (e.g. sterol regulatory element binding protein 1 (SREBP1), acetyl-CoA carboxylase (ACC), fatty acid synthase (FAS), lysophosphatidic acid acyltransferase β (LPAATβ), lipin1, diacylglycerol acyltransferases 1 (DGAT1)). The results indicated that SM70EE treatment significantly reduced the accumulation of lipid droplets in 3T3-L1 cells and down-regulated the expression of adipogenic and lipogenesis-related proteins. Changes in body weight of mice were associated with decreased expression of adipogenic factor proteins and increased expression of browning proteins (e.g., PR domain containing 16 (PRDM16), PPARγ coactivator 1 alpha (PGC1α), uncoupling protein 1 (UCP1)). This finding suggests that Spirulina maxima extract has potential applications in the prevention and treatment of obesity and related metabolic diseases.
Fig.1 Analysis of adipogenic gene and specific protein expression in SM70EE-treated mice. (Seo, et al., 2018)
Frequently Asked Questions
How to choose an appropriate preclinical obesity model?
When selecting the best analytical methods and models for preclinical biomarker studies, the following points should be considered.
- Define the target of the assay: First and foremost, define the specific biomarker or physiologic process the study is designed to detect.
- Evaluate method strengths: Existing and alternative methods are compared and the unique advantages of the selected method are identified in terms of sensitivity, specificity, and cost-effectiveness.
- Determine method use: The method is determined whether it is more suitable for discovering new biomarkers or screening known candidates.
- High-throughput compatibility: The method is examined whether it supports rapid processing of large-scale samples and meets the needs of high-throughput research.
- Data complementarity: The method is assessed for its ability to provide key information missed by other assays to ensure data comprehensiveness.
Can Protheragen still perform biomarker discovery if the client doesn't want to disclose the anti-obesity drug's identification and target?
Yes. Our expert pharmacologists customize personalized biomarker analysis solutions based on client's needs.
Combining high-quality obesity modeling and reliable analysis techniques, Protheragen provides a one-stop biomarker analysis service. No matter what type of biomarker the client wants to analyze, we are your best choice. Please feel free to contact us anytime for more information.
Reference
- Seo, Y.J.; et al. Spirulina maxima extract reduces obesity through suppression of adipogenesis and activation of browning in 3T3-L1 cells and high-fat diet-induced obese mice. Nutrients. 2018, 10(6): 712.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.